Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in adults with persistent or chronic primary immune thrombocytopenia
2019-000884-26Phase 3Terminated
- Sponsor
- UCB
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) and Thrombocytopenia comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Durable Clinically Meaningful Platelet Response. Started Feb 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)Thrombocytopenia
Beyond the preview
Go deeper on 2019-000884-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000884-26.